 Non-alcoholic fatty liver disease, NAFLD, metabolic syndrome, METS, and type 2 diabetes, T2DM, are interrelated metabolic disorders that have a significant impact on public health worldwide, with METS being a complex condition characterized by glucose intolerance, insulin resistance, dyslipidemia, associated pro-inflammatory state, and arterial hypertension. Effective management of these disorders involves early diagnosis and optimal treatment of each condition to improve glycemic and lipids regulation, liver steatosis, and arterial hypertension, which can prevent atherosclerotic cardiovascular diseases and liver fibrosis. This article was authored by Boyan Mitrovic, Zoran Gluvik, Milan Mobradovic, and others.